echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > This innovative drug industrialization base project landed in Zhangzhou, with a total investment of 2 billion yuan

    This innovative drug industrialization base project landed in Zhangzhou, with a total investment of 2 billion yuan

    • Last Update: 2020-11-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In recent years, with the vigorous development of domestic innovation, pharmaceutical companies' research and development pipeline is also constantly enriched, more and more adaptations to the clinical later stage, overlaying a series of policies such as approval and approval of innovative drugs and payment of medical insurance, the industry believes that domestic innovative pharmaceutical companies are about to usher in a period of rapid growth.
    , domestic innovative drugs also ushered in a dense market period and accelerated release period.
    this context, there is no doubt that it will also pose a challenge to the manufacturing capacity of innovative pharmaceutical companies.
    that recently, Shaoxing Zhangzhou City and Beda Pharmaceuticals in Shaoxing signed an innovative drug industrialization (Zhangzhou) base project.
    investment of the project is 2 billion yuan, in two phases of construction, one of which invests 1 billion yuan.
    the innovative drug industrialization (Zhangzhou) base project mainly built preparations, innovative raw materials and other production plants and environmental protection management facilities, while the acquisition of international and domestic production equipment.
    project is completed after the birth, the annual production of innovative drugs (raw materials) is expected to produce more than 100 tons, to achieve an annual output value of 5 billion yuan.
    Previously, Bayda Pharmaceuticals announced on September 29 that the company is a pharmaceutical research and development, production and marketing in one of the national high-tech enterprises, is currently listed products for hydrochloric acid ecquetinib (commodity name: Kemina), research and development pipeline has a number of varieties in the late clinical trial stage, will soon be approved for listing or will be declared for listing.
    company's existing industrial base space and environmental protection, safety facilities construction can not meet the company's future new product manufacturing needs.
    announcement, the company said management would coordinate the signing of the agreement as soon as possible.
    The agreement is an intentional framework agreement with an investment of RMB 1 billion for the project, which is the initial budget assuming that all relevant projects are approved and successfully implemented, and the actual amount of investment is uncertain."
    The modern pharmaceutical industry is regarded as one of the four new industries in Shaoxing's key cultivation and development, and Zhangzhou is a heavy place for the pharmaceutical industry, which has laid a very good foundation after many years of development, and is now accelerating the development of the biopharmaceutical industry.
    Among them, Zhangzhou Economic Development Zone is the main position of Zhangzhou economic construction, the region seizes the "healthy China" development opportunities, around the overall strategic positioning of building Shaoxing City's highest quality of life and health industrial park, with "one axis, one core, one ring" as the main framework, combined with the actual situation in the northern part of the city, actively build a set of biomedicine, medical equipment, health care, science and technology research and development and other diversified functions in one hundred billion yuan of life and health industrial park, initially built a domestic life and health industry cluster.
    , under the support of a series of policies in Zhangzhou Economic Development Zone, there are 12 biopharmaceutical enterprises above the scale of the area's life and health industrial park, including 2 listed enterprises.
    2019, the park achieved planned industrial sales of 7 billion yuan, up 7% YoY, of which biopharmaceutical enterprises reported industrial sales of 2.75 billion yuan, up 13.85 percent YoY.
    with the signing of the Bayda Pharmaceuticals project, it will be of great significance to enhance the development of the local biopharmaceutical industry, and will also inject strong impetus into the high-quality development of the city's manufacturing industry.
    also said that it will accelerate the project in accordance with the agreement, and strive to land early, early production, and jointly promote the development of the biopharmaceutical industry, for Shaoxing, for the province to create a new and greater contribution to the life and health section of the highland.
     
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.